Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
131 studies found for:    FGF3
Show Display Options
Rank Status Study
1 Completed Effect of Phosphate Binders on FGF-23 With Concurrent Calcitriol
Condition: Chronic Kidney Disease Stage 3
Interventions: Drug: Calcitriol;   Drug: Calcium Carbonate
2 Completed Effect of Dietary Protein Source on Phosphaturia, PTH and FGF23 in Patients With CKD 3 and 4
Condition: Chronic Kidney Disease
Interventions: Other: grain (soy) protein diet;   Other: casein (meat) protein diet
3 Completed
Has Results
Effects of Lanthanum Carbonate on FGF-23 in Subjects With Stage 3 CKD
Condition: Chronic Kidney Disease
Interventions: Drug: Lanthanum carbonate;   Drug: Placebo
4 Completed Efficacy and Safety of Intracoronary Ad5FGF-4 in Patients With Stable Angina (AGENT-3)
Condition: Angina Pectoris
Intervention: Genetic: Ad5FGF-4 vs. Placebo
5 Completed A Study to Assess the Safety of Using Fibroblast Growth Factor-2 With Periodontal Surgery in Japan (Phase 3)
Condition: Periodontitis
Intervention: Drug: Trafermin
6 Completed FGF23 Reduction : Efficacy of a New Phosphate Binder in CHronic Kidney Disease
Condition: Chronic Renal Failure
Interventions: Drug: Placebo;   Drug: Sevelamer carbonate
7 Recruiting Efficacy and Safety of Ad5FGF-4 for Myocardial Ischemia in Patients With Stable Angina Due to Coronary Artery Disease
Condition: Angina, Stable
Intervention: Genetic: Alferminogene tadenovec
8 Completed Sevelamer, FGF-23 and Endothelial Dysfunction in Chronic Kidney Disease (CKD)
Condition: We Investigated the Relationship Between Plasma FGF23 Levels and Endothelial Dysfunction in a Sizable Series of Incident Stage 3-4 CKD Patients.
Interventions: Drug: Sevelamer;   Drug: calcium acetate
9 Terminated
Has Results
Vaccine Treatment of Kidney Cancer
Condition: Kidney Cancer
Interventions: Drug: 117-126:Fibroblast growth factor 5 (FGF-5);   Drug: Fibroblast growth factor 5 (FGF-5):172-176/217-220;   Other: IL-2
10 Completed Vitamin D3 Supplementation in Dialysis Patients
Condition: End-Stage Renal Disease
Interventions: Drug: Cholecalciferol;   Drug: Placebo
11 Unknown  Angiogenesis in Women With Angina Pectoris Who Are Not Candidates for Revascularization
Condition: Angina Pectoris
Interventions: Genetic: Ad5FGF-4;   Genetic: Placebo
12 Completed Treatment of Early Stage Renal Failure With Active Vitamin D or a Phosphate Binder.
Condition: Kidney Failure
Interventions: Drug: Renvela;   Drug: Etalpha
13 Completed Bone Mineral Markers in Hypogonadism
Conditions: Hypogonadotropic Hypogonadism;   Endothelial Dysfunction;   Insulin Resistance
14 Recruiting Effect of Phosphate Binders on Markers of Vascular Health in Chronic Kidney Disease Stages 3 and 4
Condition: Chronic Kidney Disease
Interventions: Drug: Sevelamer carbonate;   Drug: Calcium acetate
15 Completed
Has Results
SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
Condition: Carcinoma, Renal Cell
Interventions: Drug: Interferon-alfa;   Drug: SU011248
16 Recruiting Regulation of FGF21 by Nutritional Challenges
Conditions: Metabolism;   Fasting;   Non-alcoholic Fatty Liver Disease (NAFLD)
Interventions: Behavioral: Fasting;   Behavioral: Diet;   Dietary Supplement: oral carbohydrate challenge
17 Terminated AS902330 in Cartilage Injury Repair (CIR)
Condition: Isolated Cartilage Injury of the Knee
Interventions: Drug: AS902330;   Other: Placebo
18 Recruiting A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
Conditions: Advanced Solid Tumors With Alterations of FGFR1, 2 and/or 3;;   Squamous Lung Cancer With FGFR1 Amplification;;   Bladder Cancer With FGFR3 Mutation or Fusion
Intervention: Drug: BGJ398
19 Recruiting Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression
Condition: Bladder Cancer
Intervention: Drug: Dovitinib
20 Unknown  Effect of Omega-3 Fatty Acid on Vitamin D Activation
Conditions: Hemodialysis Patients;   Vitamin D Insufficiency;   Vitamin D Deficiency
Interventions: Drug: Omega-3 fatty acid ethylester 90;   Other: Olive oil;   Other: cholecalciferol

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years